AbbVie Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
AbbVie Inc. (ABBV) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-18.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2022-02-18
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2020-12-31 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2020-09-30 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2020-06-30 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2019-12-31 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2021 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2020 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2019 was $0.00.
- AbbVie Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2018 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-18 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 derived: sum of 3 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 derived: sum of 3 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | $0.00 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-04 | $0.00 10-Q · filed 2020-08-04 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |